Page last updated: 2024-12-06

promegestone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

biyouyanagin A: an anti-HIV agent from Hypericum chinense L. var. salicifolium; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Promegestone: A synthetic progestin which is useful for the study of progestin distribution and progestin tissue receptors, as it is not bound by transcortin and binds to progesterone receptors with a higher association constant than progesterone. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

promegestone : A progestin consisting of 17beta-propionylestra-4,9-dien-3-one substituted at position 17 by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID70697727
CHEBI ID65510
MeSH IDM0017703
PubMed CID36709
CHEMBL ID196003
CHEBI ID73390
SCHEMBL ID37770
MeSH IDM0017703

Synonyms (52)

Synonym
(4'r)-[(1r)-1,5-dimethylhex-4-enyl]-4'-dimethyl-phenyl-4'-vinyl-spiro[[?]-[?],3'-tetrahydrofuran]-2'-dione
(2r,3as,3bs,7as,7br)-4'-ethenyl-4',7-dimethyl-4-[(2r)-6-methylhept-5-en-2-yl]-7b-phenyl-3a,3b,4,4',5,5',7a,7b-octahydro-3h-spiro[benzo[3,4]cyclobuta[1,2-b]furan-2,3'-furan]-2',3-dione
biyouyanagin a
CHEBI:65510
Q27133952
gtpl2877
surgestone
u-56217
ru-5020
r-5020
promegestona [inn-spanish]
promegestone [inn]
estra-4,9-dien-3-one, 17-alpha-methyl-17-propionyl-
r 5020
ru5020
estra-4,9-dien-3-one, 17-methyl-17-(1-oxopropyl)-, (17-beta)-
17alpha-methyl-1,7-propionylestra-4,9-dien-3-one
R5020 ,
estra-4,9-dien-3-one, 17-methyl-17-(1-oxopropyl)-, (17beta)-
promegestonum [inn-latin]
34184-77-5
promegestone
(17beta)-17-methyl-17-propionylestra-4,9-dien-3-one
(8s,13s,14s,17s)-13,17-dimethyl-17-propanoyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
surgestone (tn)
D08431
promegestone (inn)
chebi:73390 ,
CHEMBL196003
promegestonum
unii-9xe0v2sqyx
9xe0v2sqyx ,
promegestona
17,21-dimethyl-19-norpregna-4,9(10)-diene-3,20-dione
17alpha-methyl-17-propionylestra-4,9-dien-3-one
promegestone [mi]
promegestone [who-dd]
promegestone [mart.]
(10s,11s,14s,15s)-14,15-dimethyl-14-propanoyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-1,6-dien-5-one
[3h]r5020
bdbm18660
SCHEMBL37770
DTXSID4036510
(8s,13s,14s,17s)-13,17-dimethyl-17-propionyl-6,7,8,11,12,13,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
QFFCYTLOTYIJMR-XMGTWHOFSA-N
(8s,13s,14s,17s)-13,17-dimethyl-17-propionyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-3-one
DB13602
Q7249694
AT30553
HY-119384
CS-0068047
AKOS040753618

Research Excerpts

Overview

Promegestone is a potent progestin devoid of androgenic side-effects. Promegestone has marked anti-estrogenic activity.

ExcerptReferenceRelevance
"Promegestone is a potent progestin devoid of androgenic side-effects and has marked anti-estrogenic activity."( [Promegestone, a new progestin].
Ojasoo, T; Raynaud, JP, 1983
)
1.9

Pharmacokinetics

ExcerptReferenceRelevance
" The authors studied the pharmacokinetic properties of this drug in normal volunteers and patients with Cushing's syndrome using a rat progesterone radioreceptor assay."( Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man.
Brandon, DD; Chrousos, GP; Kawai, S; Loriaux, DL; Nieman, LK; Udelsman, R, 1987
)
0.27
" Oestradiol (E2) and progesterone (PG) serum concentrations, and bleeding patern were determined as pharmacodynamic parameters."( Single-dose pharmacokinetics and pharmacodynamics assessment of oestriol and trimegestone containing vaginal rings in healthy women with childbearing potential.
de Jesus Antunes, N; De Nucci, G; de Oliveira Filho, RV; de Oliveira Ilha, J; Moreno, RA; Nahoum, AF; Warnke, A; Wedemeyer, RS, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
" Treatment with a progestin, alone or in combination with estradiol, was then started and continued for 2 months."( Effect of trimegestone alone or in combination with estradiol on bone mass and bone turnover in an adult rat model of osteopenia.
Bouali, Y; Gaillard-Kelly, M; Marie, PJ, 2001
)
0.31
" The results of the study suggest that the use of trimegestone in combination with E2 may be preferable to norgestrel because of the more favorable lipid profile."( Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
Beijers-De Bie, L; De Villiers, TJ; Houben, PW; Magaril, C; Meuwissen, JH; Murga, M; Siseles, N; Spielmann, D; The, HS; Tuimala, R; Vihtamaki, T, 2002
)
0.31
"Overall, the results of this study suggest that the use of trimegestone in combination with estradiol may be preferable to norethisterone acetate because of the more favorable HDL and apo AI profile."( Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women.
Al-Azzawi, F; Proudler, AJ; Sami, S; Stevenson, J; Thompson, J; Wahab, M, 2004
)
0.32

Bioavailability

ExcerptReferenceRelevance
" We can conclude that: (1) the control of estradiol concentration can be carried out in the breast cancer tissue itself; (2) estrone sulfate can play an important role in the bioavailability of estradiol in the breast cancer cell; and (3) as is the case for the aromatase, the control of: the estrogen sulfatase, estrogen sulfotransferase, and 17 beta-hydroxysteroid dehydrogenase can be new targets for therapeutic applications in breast cancer."( Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer.
Nguyen, BL; Pasqualini, JR; Schatz, B; Varin, C, 1992
)
0.28

Dosage Studied

ExcerptRelevanceReference
" Dose-response studies reveal that 10(-6) to 10(-4) M concentrations of 8-bromo-cAMP (8-Br-cAMP) elicit a maximal response."( Progesterone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3',5'-monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors.
Aronica, SM; Katzenellenbogen, BS, 1991
)
0.28
" Dose-response studies with estrogen and R5020 revealed that the extent of progestin activity was only partially dependent upon the R5020 dose with the major determining factor being the dose of estrogen."( Progesterone action in normal mouse mammary gland.
Counterman, LJ; Haslam, SZ; Wang, S, 1990
)
0.28
" Dose-response studies indicate that high superphysiological (greater than 1 microgram/ml) concentrations of insulin are required."( Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen.
Katzenellenbogen, BS; Norman, MJ, 1990
)
0.28
" A dose-response study of progestin receptor induction in the medial preoptic nucleus (mPON), arcuate-median eminence region (ARC-ME), and VMN of male and female rats indicated a sex difference in cytosol progestin binding in the VMN at all EB doses tested (2, 8, 40, or 200 micrograms/kg body weight)."( Regional sex differences in progestin receptor induction in the rat hypothalamus: effects of various doses of estradiol benzoate.
Brown, TJ; Clark, AS; MacLusky, NJ, 1987
)
0.27
" The dose-response and time-response characteristics of the behavior facilitating actions of both progesterone and R 5020 were measured."( Actions of progestins on estrous behaviour in female rats.
Barfield, RJ; Etgen, AM; Vathy, IU, 1987
)
0.27
" Dose-response curve and specificity studies show that the accumulation of the Pg8 mRNA and that of the 250-kDa protein was increased by 5 to 30-fold following progestin treatment and that this effect was mediated by the progesterone receptor."( Cloning of cDNA sequences of a progestin-regulated mRNA from MCF7 human breast cancer cells.
Alibert, C; Chalbos, D; May, F; Rochefort, H; Westley, B, 1986
)
0.27
" The partial uterotrophic effect of monohydroxytamoxifen and full uterotrophic effects of estradiol were both inhibited by high doses of LY117018 at an approximate dosage ratio of 1:24, w/w."( Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor.
Gosden, B; Jordan, VC, 1983
)
0.27
") and at dosage sufficient to produce surgical anaesthesia and analgesia, we observed a sex difference in the efficacy of Althesin."( Sex difference in response to alphaxalone anaesthesia may be oestrogen dependent.
Borthwick, N; Dick, H; Dow, RC; Fink, G; Malnick, S; Sarkar, DK; Twine, M, 1982
)
0.26
" Dose-response analysis for R1881 revealed an ED50 of approximately 2 x 10(-8) M for the synthetic androgen, and comparison with other naturally occurring androgens provided the rank order of potency R1881 > androstenedione > testosterone = dihydrotestosterone."( Androgens augment vasoactive intestinal peptide- and growth hormone-releasing hormone-stimulated progestin production by rat granulosa cells.
Kasson, BG; Li, YD, 1993
)
0.29
" Neither differences between treated and untreated cells nor an effect of treatment duration or dosage were observed."( Endometrial integrin expression is independent of estrogen or progestin treatment in vitro.
Prifti, S; Rabe, T; Runnebaum, B; Schmidt, M; Sillem, M, 1997
)
0.3
" Because GR and coregulator concentrations simultaneously altered the position of the physiologically relevant dose-response curve, and associated EC(50), of GR-agonist complexes, we also examined this phenomenon with PR."( New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties.
Giannoukos, G; Meeker, JE; Simons, SS; Smith, CL; Szapary, D, 2001
)
0.31
"First, to compare the impact of nasally and orally dosed estradiol on breast density; second, to investigate the utility of computer-based automated approaches to the assessment of breast density with reference to traditional methods."( Parallel assessment of the impact of different hormone replacement therapies on breast density by radiologist- and computer-based analyses of mammograms.
Christiansen, C; Loog, M; Nielsen, M; Pettersen, PC; Raundahl, J; Tankó, LB, 2008
)
0.35
" In order to achieve the aim of performing large-scale dose-response analysis on the effects of lipophilic chemicals at the different cell-cycle phases, a stable, sensitive and highly selective human progesterone receptor (hPR) expressing HeLa reporter cell line, hPRLuc-20, was established."( A stable human progesterone receptor expressing HeLa reporter cell line as a tool in chemical evaluation at the different cell-cycle phases.
Matsunaga, T; Mori, T; Murata, M; Nakasono, S; Saito, F; Takeyama, H; Yoshino, T, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
progestinA synthetic progestogen.
progesterone receptor agonistA hormone agonist that binds to and activates progesterone receptors.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
terpene lactone
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Progesterone receptorHomo sapiens (human)IC50 (µMol)0.00020.00000.580710.0000AID1417058
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)1.31830.00101.979414.1600AID255211
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Progesterone receptorHomo sapiens (human)Kd0.00040.00010.00030.0004AID478060
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
ovulation from ovarian follicleProgesterone receptorHomo sapiens (human)
glandular epithelial cell maturationProgesterone receptorHomo sapiens (human)
regulation of DNA-templated transcriptionProgesterone receptorHomo sapiens (human)
signal transductionProgesterone receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayProgesterone receptorHomo sapiens (human)
cell-cell signalingProgesterone receptorHomo sapiens (human)
positive regulation of gene expressionProgesterone receptorHomo sapiens (human)
negative regulation of gene expressionProgesterone receptorHomo sapiens (human)
paracrine signalingProgesterone receptorHomo sapiens (human)
negative regulation of phosphorylationProgesterone receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
lung alveolus developmentProgesterone receptorHomo sapiens (human)
regulation of epithelial cell proliferationProgesterone receptorHomo sapiens (human)
progesterone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
maintenance of protein location in nucleusProgesterone receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisProgesterone receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
transcription coactivator bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
DNA bindingProgesterone receptorHomo sapiens (human)
nuclear steroid receptor activityProgesterone receptorHomo sapiens (human)
G protein-coupled receptor activityProgesterone receptorHomo sapiens (human)
steroid bindingProgesterone receptorHomo sapiens (human)
protein bindingProgesterone receptorHomo sapiens (human)
zinc ion bindingProgesterone receptorHomo sapiens (human)
enzyme bindingProgesterone receptorHomo sapiens (human)
identical protein bindingProgesterone receptorHomo sapiens (human)
ATPase bindingProgesterone receptorHomo sapiens (human)
estrogen response element bindingProgesterone receptorHomo sapiens (human)
nuclear receptor activityProgesterone receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneProgesterone receptorHomo sapiens (human)
nucleoplasmProgesterone receptorHomo sapiens (human)
mitochondrial outer membraneProgesterone receptorHomo sapiens (human)
cytosolProgesterone receptorHomo sapiens (human)
chromatinProgesterone receptorHomo sapiens (human)
nucleusProgesterone receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID74376Relative binding affinity to glucocorticoid receptor on cytosol from liver at 4 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID74374Relative binding affinity to glucocorticoid receptor on cytosol from hepatoma tissue cells at 4 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID74369Relative binding affinity (RBA) for glucocorticoid receptor compared to RU-283621993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Fluorine-18-labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors.
AID74378Relative binding affinity to glucocorticoid receptor on cytosol from thymus at 4 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID126435Relative binding affinity for mineralocorticoid receptor of rat kidney at 24 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID74377Relative binding affinity to glucocorticoid receptor on cytosol from thymus at 24 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID28705Partition coefficient (logP)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Fluorine-18-labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID162461Relative binding affinity against progesterone receptor at 0 degree Celsius determined in a competitive radiometric binding assay (R5020=100%).1995Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2
Fluorine-18-labeled progestin 16 alpha, 17 alpha-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity.
AID39320Relative binding affinity for androgen receptor of prostate of rat at 2 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID213396Glucocorticoid induced Tyrosine Aminotransferase activity relative to Dexamethasone1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID105817Relative binding affinity (RBA) for mineralocorticoid receptor compared to aldosterone1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Fluorine-18-labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID74373Relative binding affinity to glucocorticoid receptor on cytosol from hepatoma tissue cells at 24 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1417058Agonist activity at GAL4 DNA-binding domain fused PR (unknown origin) ligand binding domain expressed in UAS-bla HEK 293T cells assessed as beta-lactamase transcriptional activation by FRET-based GeneBLAzer assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and evaluation of 4-cycloheptylphenols as selective Estrogen receptor-β agonists (SERBAs).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1150123Relative binding affinity to rabbit progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID162460Nonspecific binding affinity against progesterone receptor was estimated relative to compound R50201995Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2
Fluorine-18-labeled progestin 16 alpha, 17 alpha-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity.
AID19440Partition coefficient (logP)1995Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2
Fluorine-18-labeled progestin 16 alpha, 17 alpha-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID162458Binding selectivity index as the ratio of RBA value to that of NSB value.1995Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2
Fluorine-18-labeled progestin 16 alpha, 17 alpha-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID162613Relative binding affinity for progestin receptor of uterus of rabbit at 24 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID74375Relative binding affinity to glucocorticoid receptor on cytosol from liver at 24 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID157436Relative binding affinity for progesterone receptor compared to R50201993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Fluorine-18-labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors.
AID478060Binding affinity to progesterone receptor2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget.
AID1346851Human Progesterone receptor (3C. 3-Ketosteroid receptors)2003Maturitas, Dec-10, Volume: 46 Suppl 1Classification and pharmacology of progestins.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (728)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990399 (54.81)18.7374
1990's178 (24.45)18.2507
2000's103 (14.15)29.6817
2010's43 (5.91)24.3611
2020's5 (0.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.18 (24.57)
Research Supply Index6.65 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials36 (4.88%)5.53%
Reviews0 (0.00%)6.00%
Reviews18 (2.44%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies5 (0.68%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
Other679 (92.01%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]